Format

Send to

Choose Destination
Rev Esp Cardiol (Engl Ed). 2015 May;68(5):398-407. doi: 10.1016/j.rec.2014.04.023. Epub 2014 Nov 29.

Non-ventricular, Clinical, and Functional Features of the RyR2(R420Q) Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia.

Author information

1
Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
2
Inserm, U769, Université de Paris Sud, IFR141, LabEx Lermit, Châtenay-Malabry, France.
3
Grupo de Investigación acreditado de Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
4
Wales Heart Research Institute, Cardiff University School of Medicine, Cardiff, United Kingdom.
5
Servicio de Histopatología, Instituto de Medicina Legal, Valencia, Spain.
6
Servicio de Histopatología, Instituto Nacional de Toxicología y Ciencias Forenses, Madrid, Spain.
7
Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: zorio_est@gva.es.

Abstract

INTRODUCTION AND OBJECTIVES:

Catecholaminergic polymorphic ventricular tachycardia is a malignant disease, due to mutations in proteins controlling Ca(2+) homeostasis. While the phenotype is characterized by polymorphic ventricular arrhythmias under stress, supraventricular arrhythmias may occur and are not fully characterized.

METHODS:

Twenty-five relatives from a Spanish family with several sudden deaths were evaluated with electrocardiogram, exercise testing, and optional epinephrine challenge. Selective RyR2 sequencing in an affected individual and cascade screening in the rest of the family was offered. The RyR2(R420Q) mutation was generated in HEK-293 cells using site-directed mutagenesis to conduct in vitro functional studies.

RESULTS:

The exercise testing unmasked catecholaminergic polymorphic ventricular tachycardia in 8 relatives (sensitivity = 89%; positive predictive value = 100%; negative predictive value = 93%), all of them carrying the heterozygous RyR2(R420Q) mutation, which was also present in the proband and a young girl without exercise testing, a 91% penetrance at the end of the follow-up. Remarkably, sinus bradycardia, atrial and junctional arrhythmias, and/or giant post-effort U-waves were identified in patients. Upon permeabilization and in intact cells, the RyR2(R420Q) expressing cells showed a smaller peak of Ca(2+) release than RyR2 wild-type cells. However, at physiologic intracellular Ca(2+) concentration, equivalent to the diastolic cytosolic concentration, the RyR2(R420Q) released more Ca(2+) and oscillated faster than RyR2 wild-type cells.

CONCLUSIONS:

The missense RyR2(R420Q) mutation was identified in the N-terminus of the RyR2 gene in this highly symptomatic family. Remarkably, this mutation is associated with sinus bradycardia, atrial and junctional arrhythmias, and giant U-waves. Collectively, functional heterologous expression studies suggest that the RyR2(R420Q) behaves as an aberrant channel, as a loss- or gain-of-function mutation depending on cytosolic intracellular Ca(2+) concentration.

KEYWORDS:

Calcio; Calcium; Canales iónicos; Electrocardiografía; Electrocardiography; Genetics; Genética; Ion channels; Muerte súbita; Receptor 2 de rianodina; Ryanodine receptor-2; Sudden death

PMID:
25440180
DOI:
10.1016/j.rec.2014.04.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center